Optimization and Refinement of Technique in In-Office Sinus Dilation 2 (ORIOS2)

This study has been completed.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: April 12, 2010
Last updated: March 19, 2014
Last verified: March 2014

A prospective, single-arm, multi-center, post-market study of balloon sinus dilatation in the physician office setting under local anesthesia to treat chronic rhinosinusitis (CRS). All products intended for use in this study have been FDA cleared for sale in the U.S.A.

Condition Intervention
Device: Relieva Balloon Sinuplasty System

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Optimization and Refinement of Technique in In-Office Sinus Dilation 2 (ORIOS 2)

Resource links provided by NLM:

Further study details as provided by Acclarent:

Primary Outcome Measures:
  • Change of Lund-MacKay CT scan scores and SNOT-20 scores at baseline and 24-weeks [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Tolerability and Pain scores on a visual analog scale [ Time Frame: Day 0 (Day of Procedure) ] [ Designated as safety issue: No ]
    Procedure Tolerability: Tolerability will be based on subject-reported pain during and immediately following the procedure. Pain and subject tolerability of the procedure will be reported using Visual Analog Scale (VAS) and the global assessment questionnaire.

Enrollment: 203
Study Start Date: April 2010
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Balloon device
Treatment of sinusitis using balloon tools
Device: Relieva Balloon Sinuplasty System
Sinuplasty balloon tools for treatment of chronic rhinosinusitis


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adult subjects with diagnosis of CRS and planned endoscopic sinus surgery.


Inclusion Criteria:

  • Male/Female, 18 year or older
  • Diagnosis of Chronic Rhinosinusitis
  • Planned Endoscopic Sinus surgery

Exclusion Criteria:

  • Cystic Fibrosis
  • Severe Polyposis
  • Sinonasal tumors
  • History of facial trauma precluding access to sinus ostium
  • Ciliary Disfunction
  • Planned non-sinus surgery (such as rhinoplasty, septoplasty, etc.)
  • Pregnant or lactating female
  • Inability to tolerate an awake procedure
  • Participation in another investigational clinical study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01107379

United States, Alabama
Birmingham, Alabama, United States, 35242
Sponsors and Collaborators
Principal Investigator: Michael Sillers, MD Alabama Nasal and Sinus Center
  More Information

No publications provided by Acclarent

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Acclarent
ClinicalTrials.gov Identifier: NCT01107379     History of Changes
Other Study ID Numbers: CPR005010
Study First Received: April 12, 2010
Last Updated: March 19, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Paranasal Sinus Diseases
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases

ClinicalTrials.gov processed this record on August 28, 2014